This is the comment from the announcement of the 510k approval which seems to indicate the price for BTM will be skewed to the reimbursement level and not the cost plus margin basis. BTM is cheaper to make than competitors and gives a better outcome for patients and is easier to use for Doctors. I guess PNV should receive a significantly better margin than others in the space and this as well as other advantages justifies the "disruptive" comment in the same announcement.
From the announcement on the 4th January 2016
"Reimbursement of the dermal matrixes in hospitals and alternate care facilities is an established process with prices established on a surface area and application basis."
Cheers
Waiting for licencing agreement to be announced, page-12
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.33 |
Change
-0.020(0.85%) |
Mkt cap ! $1.608B | |||
| Open | High | Low | Value | Volume |
| $2.32 | $2.34 | $2.29 | $1.770M | 763.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5901 | $2.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.34 | 6302 | 2 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |